Search Within

Weinberg Fellows

Formats
  1. Meeting Abstract (1256)
  2. Journal Article (1061)
  3. Review (108)
  4. Editorial (54)
  5. Research Letter (31)
  6. Book Section (22)
  7. Correspondence (20)
  8. Guidelines (12)
  9. Conference Paper (2)
  10. Miscellaneous (1)
Groups
  1. Department of Medicine (2470)
  2. Solid Tumor Oncology Division (1885)
  3. Hematologic Malignancies, Division of (1191)
  4. GSK Faculty (1125)
  5. Department of Pathology and Laboratory Medicine (917)
  6. Epidemiology and Biostatistics (863)

More Groups

People
  1. Michael Berger (215)
  2. Marc Ladanyi (191)
  3. Pedram Razavi (184)
  4. Michael Offin (173)
  5. David Solit (166)
  6. Maria Carlo (166)

More People

Years
  1. 2025 (152)
  2. 2024 (370)
  3. 2023 (292)
  4. 2022 (347)
  5. 2021 (307)
  6. 2020 (307)

More Years

Publications
  1. Journal of Clinical Oncology (547)
  2. Blood (248)
  3. Annals of Oncology (98)
  4. Clinical Cancer Research (95)
  5. Journal of Thoracic Oncology (82)
  6. Cancer Research (80)

More Publications

Publishers
  1. American Society of Clinical Oncology (618)
  2. Elsevier Inc. (355)
  3. American Society of Hematology (282)
  4. American Association for Cancer Research (217)
  5. Nature Publishing Group (177)
  6. Oxford University Press (147)

More Publishers

Results (2567)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Comparison of patients with newly diagnosed (ND) acute myeloid leukemia (AML) treated with venetoclax and hypomethylating agents vs other therapies by TP53 and IDH1/2 mutation: Results from the AML Real World Evidence (ARC) Initiative
    Meeting Abstract

    Wolach, O.; Garcia, J. S.; Desai, P.; Vachhani, P.; Zeidner, J. F.; Abedin, S.; Sweet, K.; Lai, C.; Moshe, Y.; Pollyea, D. A.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Allogeneic hematopoietic cell transplantation in patients with relapsed or refractory acute leukemia
    Meeting Abstract

    Elias, S.; Walji, M.; Brown, S.; Devlin, S. M.; Papadopoulos, E. B.; Jakubowski, A. A.; Ponce, D. M.; Young, J. W.; Giralt, S. A.; Perales, M. A.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • An ongoing pilot study of targeted radioimmunotherapy (131-I apamistamab) conditioning prior to CD19-targeted CAR T-cell therapy for relapsed or refractory B-cell acute lymphoblastic leukemia or diffuse large B-cell lymphoma
    Meeting Abstract

    Geyer, M. B.; Cadzin, B.; Hosszu, K.; Senechal, B.; Spross, J. A.; Mark, A.; Desai, A.; Cathcart, E. R.; Palomba, M. L.; Pandit-Taskar, N.
    Blood (2022)

    Fulltext@MSK | Save
  • Molecular profiling across lymphoma subtypes using MSK-impact next generation sequencing
    Meeting Abstract

    Batlevi, C. L.; Drill, E.; Okwali, M.; Ptashkin, R.; Caron, P. C.; Epstein-Peterson, Z. D.; Falchi, L.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Immune signature of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma
    Meeting Abstract

    Wills, B.; Ganesan, N.; Shah, G. L.; Wong, P.; Argyropoulos, K. V.; Sen, F.; Dogan, A.; Straus, D. J.; Noy, A.; Kumar, A.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Quantitative cytogenetic analysis with karyoParser allows for more precise identification of disease biology, clonal evolution, and etiology of relapse in acute myeloid leukemia
    Meeting Abstract

    Dilip, D.; Derkach, A.; Menghrajani, K.; Goldberg, A. D.; May, H.; Klimek, V. M.; Galera, P. K.; Xiao, W.; Zhang, Y.; Elemento, O.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Intensive therapy for NPM1 mutant AML patients: Negative impact of FLT3-ITD(high)but not FLT3-ITD(low) and FLT3TKD and role of transplant in patients over 60 years of age
    Meeting Abstract

    Winer, E. S.; Flamand, Y.; Shallis, R. M.; Stempel, J. M.; Goldberg, A. D.; Stahl, M. F.; Patel, A. A.; Duvall, A. S.; Abaza, Y.; Oh, T. S.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • A phase 1a/b dose escalation study of the FLT3/BTK inhibitor luxeptinib (CG-806) in patients with relapsed or refractory acute myeloid leukemia
    Meeting Abstract

    Goldberg, A. D.; Ohanian, M.; Koller, P. B.; Cherry, M.; Altman, J. K.; Tomlinson, B.; Chandhok, N. S.; Haney, D. N.; Hu, J.; Sinha, R. K.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Clinical outcomes of patients with TP53-mutated AML after first relapse or with primary refractory disease: Results from consortium on myeloid malignancies and neoplastic diseases (COMMAND)
    Meeting Abstract

    Badar, T.; Atallah, E. L.; Saliba, A. N.; Shallis, R. M.; Stahl, M. F.; Bewersdorf, J. P.; Correia, G. S. D.; Patel, A. A.; Abaza, Y.; Murthy, G. S. G.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • OGDH Is a genetic vulnerability and therapeutic target in acute myeloid leukemia
    Meeting Abstract

    Millman, S. E.; Chaves-Perez, A.; Morris, J. P. 4th; Chen, C. C.; Ho, Y. J.; Raman, S. J.; Yashinskie, J. J.; Mezzadra, R.; Narendra, V.; Tian, S.; more...
    Blood (2022)

    Fulltext@MSK | Save